Chandra Bhagat

Why is Chandra Bhagat Pharma Ltd falling/rising?

As of 12-Jun, Chandra Bhagat Pharma Ltd's stock price is stable at 43.90, but it has declined significantly by 25.53% over the past year and 69.51% over three years. Despite recent short-term gains, investor participation has dropped sharply, indicating ongoing uncertainty.

As of 12-Jun, Chandra Bhagat Pharma Ltd's stock price is currently stable at 43.90, showing no change (0.00%). Despite this stability, the stock has experienced a significant decline over the past year, with a decrease of 25.53%, and a notable drop of 69.51% over the last three years. <BR><BR>In terms of recent performance, the stock has outperformed its sector by 0.26% today, indicating some positive movement relative to its peers. However, the stock has shown erratic trading patterns, having not traded on 4 out of the last 20 days, which may contribute to investor uncertainty. Additionally, there has been a substantial decline in investor participation, with delivery volume dropping by 95.9% against the 5-day average, suggesting a lack of confidence among investors.<BR><BR>While the stock has performed well over the past month, with a rise of 38.92%, this is contrasted by its year-to-date performance of only 6.42%, which is still positive compared to the Sensex's decline of 11.37%. The moving averages indicate that the stock is currently higher than the 5-day, 20-day, and 50-day averages but lower than the 100-day and 200-day averages, which may reflect a mixed sentiment among investors.<BR><BR>Overall, while there are some positive indicators in the short term, the long-term decline and recent drop in trading activity suggest that the stock's price is not rising significantly at this time.

Which are the latest news on Chandra Bhagat?

What does Chandra Bhagat do?

Chandra Bhagat Pharma Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2003 and converted to a Public Limited Company in 2019. It currently has no available sales or profit data, with a market cap of INR 33 Cr and a P/E ratio of 11.00.

Overview:<BR>Chandra Bhagat Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated in 2003 as "Chandra Bhagat Pharma Private Limited" and later converted to a Public Limited Company, changing its name to "Chandra Bhagat Pharma Limited" on March 20, 2019. There is no sales or profit data available for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 33 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 11.00<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt Equity: 0.61<BR>Return on Equity: 10.03%<BR>Price to Book: 1.09<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are in the management team of Chandra Bhagat?

The management team of Chandra Bhagat includes Hemant C Bhagat (Chairman & Managing Director), Pranav H Bhagat (Whole-time Director), Prachi Pranav Bhagat (Director & CFO), and independent directors Ravindra Gajanan Awati and Abha Praveen Doshi.

The management team of Chandra Bhagat includes the following individuals:<BR><BR>1. **Hemant C Bhagat** - Chairman & Managing Director<BR>2. **Pranav H Bhagat** - Whole-time Director<BR>3. **Prachi Pranav Bhagat** - Director & CFO<BR>4. **Ravindra Gajanan Awati** - Independent Director<BR>5. **Abha Praveen Doshi** - Independent Director<BR><BR>If you need more details about their roles or the company's operations, feel free to ask!

Who are the peers of the Chandra Bhagat?

Chandra Bhagat's peers include Murae Organisor, Lasa Supergeneri, Roopa Industries, Medi Caps, Welcure Drugs, Guj. Terce Labs., Shree Ganesh Bio, Venmax Drugs, and Centuple Global. Management risk is generally below average for most peers, with Centuple Global showing the best returns at 105.84% over one year, while Chandra Bhagat's return is -24.31%.

Peers: The peers of Chandra Bhagat are Murae Organisor, Lasa Supergeneri, Roopa Industries, Medi Caps, Welcure Drugs, Guj. Terce Labs., Shree Ganesh Bio, Venmax Drugs, Centuple Global.<BR><BR>Quality Snapshot: Below Average management risk is observed at Murae Organisor, Lasa Supergeneri, Roopa Industries, Medi Caps, Chandra Bhagat, Guj. Terce Labs., Shree Ganesh Bio, and Venmax Drugs, while Average management risk is found at Welcure Drugs, and Good management risk is noted at Centuple Global. Growth is Excellent at Roopa Industries, Good at Murae Organisor and Centuple Global, Below Average at Lasa Supergeneri, Medi Caps, Chandra Bhagat, Guj. Terce Labs., Shree Ganesh Bio, and Welcure Drugs, and Average at Venmax Drugs. Capital Structure is Good at Medi Caps, Welcure Drugs, Shree Ganesh Bio, Below Average at Murae Organisor, Lasa Supergeneri, Chandra Bhagat, Guj. Terce Labs., and Venmax Drugs, and Average at Centuple Global.<BR><BR>Return Snapshot: Centuple Global has the highest 1-year return at 105.84%, while Murae Organisor has the lowest at -83.76%. Chandra Bhagat's 1-year return of -24.31% is better than Murae Organisor's but worse than Centuple Global's. Additionally, the six-month return is negative for Welcure Drugs, Guj. Terce Labs., Shree Ganesh Bio, Venmax Drugs, and Centuple Global.

When is the next results date for Chandra Bhagat Pharma Ltd?

The next results date for Chandra Bhagat Pharma Ltd is 25 May 2026.

The next results date for Chandra Bhagat Pharma Ltd is scheduled for 25 May 2026.

How has been the historical performance of Chandra Bhagat?

Chandra Bhagat's historical performance shows significant declines in net sales and profits from March 2024 to March 2025, with net sales dropping from 221.37 Cr to 86.72 Cr and increasing debt levels from 16.43 Cr to 20.86 Cr, indicating a challenging financial environment.

Answer:<BR>The historical performance of Chandra Bhagat shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Chandra Bhagat's net sales peaked at 221.37 Cr in March 2024 but dropped to 86.72 Cr by March 2025. The total operating income followed a similar trend, decreasing from 221.37 Cr in March 2024 to 86.72 Cr in March 2025. The total expenditure also saw a decline, from 228.42 Cr in March 2024 to 88.18 Cr in March 2025. Operating profit (PBDIT) was negative in both March 2025 and March 2024, at -1.46 Cr and -7.05 Cr respectively, indicating a challenging operational environment. Profit before tax showed a slight decrease from 2.26 Cr in March 2024 to 1.17 Cr in March 2025, while profit after tax also fell from 1.53 Cr to 0.86 Cr in the same period. The company's total assets remained relatively stable, slightly decreasing from 101.78 Cr in March 2024 to 101.46 Cr in March 2025. Total debt increased from 16.43 Cr to 20.86 Cr, reflecting a rise in financial obligations. Cash flow from operating activities was consistent, with 6.00 Cr in March 2024 and 5.00 Cr in March 2023, but the net cash flow turned negative in March 2024 at -1.00 Cr. Overall, Chandra Bhagat's financial performance indicates a decline in sales and profits, alongside increasing debt levels, suggesting a need for strategic adjustments.

Is Chandra Bhagat overvalued or undervalued?

As of May 30, 2025, Chandra Bhagat's valuation has been downgraded to risky due to overvaluation, with a PE ratio of 42.25 and an EV to EBITDA of -36.70, significantly underperforming its peers and the market.

As of 30 May 2025, the valuation grade for Chandra Bhagat has moved from does not qualify to risky, indicating a significant downgrade in its investment attractiveness. The company is currently considered overvalued, especially when compared to its peers. Key ratios include a PE ratio of 42.25, an EV to EBITDA of -36.70, and a ROE of 3.03%. <BR><BR>In comparison, Sun Pharmaceutical Industries Ltd. has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla Ltd. shows a more favorable PE of 22.99 and an EV to EBITDA of 15.93, both suggesting better valuation metrics. Additionally, Chandra Bhagat's stock has underperformed significantly, with a year-to-date return of -15.15% compared to a 5.58% return for the Sensex, reinforcing the notion that the stock is overvalued in its current state.

What is the technical trend for Chandra Bhagat?

As of June 4, 2025, Chandra Bhagat's technical trend is mildly bearish, with conflicting signals from indicators like the weekly MACD being mildly bullish and the monthly MACD remaining bearish, while daily moving averages also suggest caution.

As of 4 June 2025, the technical trend for Chandra Bhagat has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands and KST are both mildly bearish on the weekly and monthly time frames. The moving averages on the daily chart are bearish, which adds to the overall cautious outlook. The Dow Theory shows a mildly bullish signal on the weekly but is bearish on the monthly. The On-Balance Volume (OBV) is mildly bullish on both weekly and monthly charts, suggesting some accumulation. Overall, the current technical stance is mildly bearish, with key indicators such as the daily moving averages and monthly MACD contributing to this view.

Who are the top shareholders of the Chandra Bhagat?

The top shareholders of Chandra Bhagat include Hemant Chandravadan Bhagat with 35.5%, Team Anamika Algo Limited at 9.5%, and individual investors holding 11.16%. There are no pledged promoter holdings or mutual funds invested in the company.

The top shareholders of Chandra Bhagat include the promoters, with Hemant Chandravadan Bhagat holding the largest share at 35.5%. The highest public shareholder is Team Anamika Algo Limited, which owns 9.5%. Additionally, individual investors collectively hold 11.16% of the shares. There is also one foreign institutional investor (FII) that holds 0.61% of the company's shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

how big is Chandra Bhagat?

As of Jun 05, Chandra Bhagat Pharma Ltd has a market capitalization of 46.00 Cr, classifying it as a Micro Cap company. There is no available financial data for the latest four quarters, but as of March 2024, Shareholder's Funds are valued at 29.01 Cr, with Total Assets of 101.78 Cr.

Market Cap: As of Jun 05, Chandra Bhagat Pharma Ltd has a market capitalization of 46.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid Consolidated or Standalone financial data available for the latest four quarters, including figures for Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of March 2024. The Shareholder's Funds are valued at 29.01 Cr, and the Total Assets amount to 101.78 Cr.

Has Chandra Bhagat declared dividend?

No Dividend History Available